Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016" report to their offering.

Idiopathic (Essential) Hypertension pipeline therapeutics constitutes close to 14 molecules. which approximately 14 molecules are developed by Companies. Idiopathic (Essential) Hypertension - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Idiopathic (Essential) Hypertension Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of hypertension that by definition has no identifiable cause. Essential hypertension increases with age, and individuals with relatively high blood pressure at younger ages are at increased risk for the subsequent development of hypertension. Hypertension increases the risk of cerebral, cardiac, and renal events. It can be caused by genetic predisposition, age and lifestyle habits such as inadequate physical activity, a high fat diet and high salt intake. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 1, 1 and 1 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Idiopathic (Essential) Hypertension Overview
  3. Therapeutics Development
  4. Pipeline Products for Idiopathic (Essential) Hypertension - Overview
  5. Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis
  6. Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies
  7. Idiopathic (Essential) Hypertension - Therapeutics under Investigation by Universities/Institutes
  8. Idiopathic (Essential) Hypertension Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Idiopathic (Essential) Hypertension - Products under Development by Companies
  13. Idiopathic (Essential) Hypertension - Products under Investigation by Universities/Institutes
  14. Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development
  • Actelion Ltd
  • Bayer AG
  • Chong Kun Dang Pharmaceutical Corp.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • HanAll Biopharma Co., Ltd.
  • Innopharmax Inc.
  • Lee's Pharmaceutical Holdings Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Quantum Genomics SA
  • Takeda Pharmaceutical Company Limited

For more information about this report visit http://www.researchandmarkets.com/research/59tt5m/idiopathic

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005952/en/

Business Wire
www.businesswire.com

Last updated on: 28/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.